By Josh Beckerman

Shares of Sonnet BioTherapeutics Holdings Inc. were up 8% to $1.40 after it announced a clinical collaboration agreement with Roche Holding AG.

In Sonnet's first combination clinical study, Sonnet's SON-1010 and Roche's atezolizumab will be evaluated in patients with platinum-resistant ovarian cancer.

Sonnet expects to begin the study in the second quarter.

In October, Sonnet announced a collaboration agreement with Janssen Biotech Inc., which is part of Johnson & Johnson. It said SON-1010, SON-1210 and SON-1410 would be evaluated in combination with certain Janssen proprietary cell therapy assets.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

January 09, 2023 13:25 ET (18:25 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Roche (QX) Charts.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Roche (QX) Charts.